Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?

Pierre Miossec

The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis

Perturbed epigenetic landscape and deregulated microRNA networks are central to the permanent activation and aggressiveness of synovial fibroblasts in rheumatoid arthritis. Current anti-cytokine therapies, alt...

Authors: Mojca Frank-Bertoncelj and Steffen Gay

Citation: Arthritis Research & Therapy 2014 16:117

Content type: Commentary Published on: 26 June 2014
- View Full Text
- View PDF
The quest for personalized B-cell depletion therapy in rheumatic disease

Although B cell depletion therapy (BCDT) is now a well-accepted therapeutic option in autoimmune rheumatic disease, a significant proportion of patients remain resistant to therapy. .19pt?>A more challenging c...

Authors: Kiran Nistala and Claudia Mauri

Citation: Arthritis Research & Therapy 2014 16:116

Content type: Commentary Published on: 26 June 2014
- View Full Text
- View PDF
Why is there persistent disease despite biologic therapy? Importance of early intervention

This short article hypothesizes that the major reason for persistent disease despite biologic therapy is the inappropriately late timing of therapy with biologic agents. There is clear evidence to support this...

Authors: Paul Emery

Citation: Arthritis Research & Therapy 2014 16:115

Content type: Commentary Published on: 26 June 2014
- View Full Text
- View PDF
The disease formerly known as rheumatoid arthritis

Rheumatoid arthritis is a complex disease where predetermined and stochastic factors conspire to confer disease susceptibility. In light of the diverse responses to targeted therapies, rheumatoid arthritis mig...

Authors: Gary S Firestein

Citation: Arthritis Research & Therapy 2014 16:114

Content type: Commentary Published on: 26 June 2014
- View Full Text
- View PDF
Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’

Authors: Pierre Miossec

Citation: Arthritis Research & Therapy 2014 16:113

Content type: Commentary Published on: 26 June 2014
- View Full Text
- View PDF

Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?

The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis

The quest for personalized B-cell depletion therapy in rheumatic disease

Why is there persistent disease despite biologic therapy? Importance of early intervention

The disease formerly known as rheumatoid arthritis

Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’